ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)
ABBOTT LABORATORIES · Decision date Feb 12, 2026
What did the FDA decide?
FDA records P120008/S031 as a supplement to PMA P120008, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.
FDA approval order statement
change to a new supplier of a manufacturing ingredient
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Immunology
- Decision date
- Feb 12, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P120008/S031
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT LABORATORIES
- Product code
- LOK
- Decision code
- OK30
- Decision date
- Feb 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.
- Applicant
- ABBOTT LABORATORIES
- Product code
- LOK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P120008/S031 received
Application receipt date recorded by FDA.
P120008/S031 · FDA decision
30-Day Notice
P120008/S032 · Related supplement
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)
Timeline entries are records held by MedtechLedger for P120008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S032 | ABBOTT LABORATORIES | PMA supplement | May 11, 2026 | FDA |
Explore the linked device profile
Other records with product code LOK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems AFPP010007/S028 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
IMMULITE Systems AFPP010007/S027 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 AFPP010007/S026 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Jul 27, 2026 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | May 11, 2026 | FDA | |
IMMULITE 2000 AFPP010007/S025 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Apr 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ABBOTT LABORATORIES
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 09v6 Ap5-2n, 100 Abbott Park Rd., Abbott Park, IL, 60064
Sources and methodology
- Original FDA record: P120008/S031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



